Effectiveness and Safety of Niraparib as Neoadjuvant Therapy in Advanced Ovarian Cancer With Homologous Recombination Deficiency (NANT): Study Protocol for a Prospective, Multicenter, Exploratory, Phase 2, Single-Arm Study

Background: Ovarian cancer (OC) is a heterogeneous gynecological malignancy with a poor prognosis as the majority of patients are diagnosed at an advanced stage. Neoadjuvant chemotherapy (NACT) followed by interval debulking surgery (IDS) is recommended for patients who cannot achieve optimal cytoreduction or cannot endure primary debulking surgery (PDS). As there is an increased risk of chemoresistance for platinum-based NACT, it is important to investigate an alternative option. A Poly (ADP-ribose) polymerase inhibitor (PARPi), niraparib, has shown high anti-tumor activity, especially in homologous recombination deficiency (HRD) positive patients with OC. Thus, niraparib as a neoadjuvant treatment agent may help improve surgery accessibility and create survival benefits.

Methods: This multicenter, prospective, single-arm, open-label, phase II study plans to recruit 53 patients (aged 18-75 years) with newly diagnosed HRD positive, unresectable (Fagotti score ≥ 8 or upper abdominal computed tomography [CT] score ≥ 3) International Federation of Gynecology and Obstetrics (FIGO) stage III-IV OC. The HRD status was detected by next-generation sequencing and HRD positive patients will be counseled for study participation. Enrolled patients will receive niraparib capsules QD (200mg or 300mg per day) for two cycles (4 weeks/cycle). After neoadjuvant niraparib treatment, patients exhibiting complete response (CR), partial response (PR), or stable disease (SD) will undergo tumor reduction surgery and subsequent standard carboplatin/paclitaxel-based chemotherapy. The primary objectives include the objective response rate (ORR) and R0 resection rate. The rate of treatment interruption/termination and progression-free survival (PFS) will be secondary objectives. The study uses Simon’s optimal two-stage design (24 and 21 patients for the first and second stage respectively). The data manager will record all adverse events (AEs).

Discussion: This is the first prospective study to evaluate the effectiveness and safety of niraparib in neoadjuvant treatment for advanced OC. The result of this study will provide a solid base for further expanding the clinical applications of the PAPRi and exploring more therapeutic possibilities for patients with HRD positive advanced OC. Clinical Trial Registration: https://clinicaltrials.gov/, identifier NCT04507841.

Introduction

Cancer statistics in China indicated that there is an increasing incidence and mortality due to cancer with about 55,342 (17.6%) new ovarian cancer (OC) cases and 37,519 (18.1%) deaths in 2020 (1). The world OC coalition 2020 reported China with the largest number of women with OC in terms of incidence and 5-year prevalence (2). The majority of OCs are at an advanced stage corresponding to stages II b to IV of the International Federation of Gynecology and Obstetrics (FIGO) classification, resulting in poor prognosis (3, 4). Advanced stage presentation has a 5-year relative survival rate of 29% (5). The size of the residual lesion after surgery is an important prognostic factor for survival, so the 5-year survival rate is even worse for those who cannot receive optimal resection.

Standard therapy as per NCCN guidelines for patients with OC (2021) includes surgical debulking or cytoreductive surgery (residual disease <1 cm [R1] and removal of macroscopic disease [R0]) followed by platinum-based chemotherapy (6, 7). If optimal resection (R0 and R1) cannot be achieved, platinum-based neoadjuvant chemotherapy (NACT) with interval debulking surgery (IDS) should be considered (6). Sub-optimal debulking and platinum resistance predominantly leads to treatment failure and high mortality. Hence, complete R0 resection and platinum sensitivity are important for prolonging survival (8). NACT increased the chances of complete resection thereby resulting in improved progression-free survival (PFS) and overall survival (OS) theoretically (9). However, according to previous reports, survival benefits brought by increased R0 resection rate may be diminished by NACT-induced platinum resistance. Evidence showed that NACT may enhance cancer cell stemness, which may lead to chemoresistance, and patients who underwent NACT may experience more platinum resistance and shorter platinum-free interval for recurrence (10, 11). As the platinum-containing regimen in NACT may induce resistance at a later stage, therefore it is important to use an alternative non-platinum-based NACT to avoid platinum chemoresistance and to produce complete R0 resection opportunity in patients with advanced OC.

Evidenced by multiple clinical trials, poly (ADP-ribose) polymerase (PARP) inhibitors (including olaparib, niraparib, veliparib, etc.) have revolutionized the treatment paradigm of OC by eliminating HRD positive or BRCA 1/2 mutated tumors (12–15). The anti-cancer activities of PARP inhibitors have been confirmed step by step from the late-line to the front-line maintenance therapy (16). Among these drugs, niraparib, an efficient FDA (Food and Drug Administration)-approved PARP 1/2 inhibitor, showed competence as monotherapy for the late-line treatment of OC, with an overall response rate of 28% in homologous recombination deficiency (HRD) positive patients (95% CI 15.6-42.6; one side P=0.00053) (17). Based on the QUADRA trial, the FDA approved niraparib to treat HRD positive ovarian cancer patients with platinum-sensitive relapse after ≥3 line chemotherapy. Thus, niraparib might serve as an alternative agent for platinum-based NACT in patients with HRD positive OC. Besides, chemotherapy-naïve OC was more sensitive to platinum, as compared to recurrent tumors, implying the potential for a better anti-cancer efficiency of niraparib if served as neoadjuvant therapy.

Therefore, it can be hypothesized that applying neoadjuvant niraparib could reduce platinum resistance and ensure maximum benefit from cytoreductive surgery and postoperative chemotherapy in ovarian cancer patients with HRD positive, unresectable or intolerable to surgery, and ultimately lead to improved prognosis. And the present study is conducted aiming to assess the efficiency and safety of niraparib in newly diagnosed advanced OC.

Methods

Study Design

This multicenter, prospective, interventional, single-arm, open-label, phase II study plans to recruit 53 women from 10 centers from China. This study will be conducted in accordance with the protocol, the current version of the Declaration of Helsinki, Good Clinical Practices (GCP) guidelines and any local regulations. The study has been registered at ClinicalTrials.gov (NCT04507841) was approved by the China-South East and Middle Gynecological Oncology Group (CSEM GOG-017). This trial was also approved by the Research Ethics Commission of Tongji Medical College of Huazhong University of Science and Technology (2020-S122). Informed consents will be obtained from patients both before screening and before receiving niraparib treatment.

The study design is provided in Figure 1. Treatment-naïve patients (aged 18-75 years) with newly diagnosed, HRD positive, low likelihood of optimal cytoreduction by computed tomography evaluation ≥3 or Fogotti score ≥8, FIGO stage III-IV OC will be included. The detailed inclusion and exclusion criteria are provided in Table 1. Informed consent will be obtained before HRD testing and receiving niraparib treatment, and the choice of treatment will depend on patients’ preferences. All enrolled patients will receive a minimum of 200mg or 300mg QD of niraparib as 100 mg capsules for 2 cycles each lasting for 28 days. The initial dose will be adjusted according to the baseline body weight and platelet count (≥77 kg and 150000/UL, 300 mg dose is recommended; otherwise 200 mg dose). After receiving niraparib for 2 cycles, abdominal computed tomography (CT) scan will be performed to classify objective remission status according to Response Evaluation Criteria in Solid Tumors (RECIST version 1.1). If patients achieve complete response (CR), partial response (PR) or stable disease (SD), they will receive open laparotomy IDS. Post-surgery, routine platinum-based chemotherapy will be given for 6 cycles, following which, niraparib will be given as maintenance therapy within 12 weeks up to 3 years or till disease progression or patient withdrawal from the study since they are high risk of recurrence and demonstrated efficacy in neoadjuvant therapy. However, patients with progression disease (PD) will receive NACT and follow-up therapy as recommended by the NCCN guidelines. In the case of grade 3-4 adverse events (AEs), the treatment should be suspended, and the AEs should be actively treated until returning to grade 1-2. The dose may be reduced in the next cycle of treatment depending on the decision of the investigators. If the toxicity does return to grade 1-2 or below within 28 days, no further reduction below 100mg/day will be allowed.

FIGURE 1

Figure 1 Study Design. *Blood and tissue samples were collected at various stages i.e., before and during treatment, disease progression/recurrence, during surgery and post-operative chemotherapy and follow-up. **CA-125 was determined as per Gynecologic Cancer Intergroup Consensus (GCIC) guidelines. ***Abdominal CT or laparoscopy is recommended to classify objective remission status. CA-125, cancer antigen-125; CR, complete response; CT, computed tomography; FIGO, International Federation of Gynecology and Obstetrics; HRD, homologous recombination deficiency; NACT, neoadjuvant chemotherapy; N, number; PD, progressive disease; PR, partial response; RECIST, Response Evaluation Criteria in Solid Tumors; SD, stable disease; TC, Paclitaxel and carboplatin regimen.

TABLE 1

Table 1 Key inclusion and exclusion criteria.

Study Objectives and Endpoints

The primary objective is to evaluate objective response rate (ORR) and R0 resection rate after niraparib neoadjuvant treatment. ORR is defined by the rate of patients achieving CR or PR. The secondary endpoints will be to evaluate the number of patients with treatment-related AEs or serious AEs as assessed by Common Terminology Criteria for Adverse Events (CTCAE version 5.0). Furthermore, the rate of treatment interruption and termination caused by patients’ intolerance of side effects, incidence of AEs at all levels during the course of the treatment, surgery and chemotherapy following treatment will also be determined. The secondary efficacy endpoints will be to determine disease control rate (DCR); pathologic complete response rate measured by Miller-Panye system; PFS; cancer antigen 125 (CA125) progression rate as per Gynecologic Cancer Intergroup Consensus (GCIC) guidelines; OS and long-term benefits including chemotherapy-free interval (CFI) and time to first subsequent therapy (TFST). The definitions of primary secondary endpoints are provided in Table 2.

TABLE 2

Table 2 Primary and secondary endpoints.

For assessing quality of life (QOL), validated patient report outcome (PRO) tools will be used namely, Functional Assessment of Cancer Therapy-Ovarian (FACT-O), Hospital Anxiety and Depression Scale (HADS), Insomnia Severity Index (ISI), International Physical Activity Questionnaire (IPAQ), EuroQol-visual analog scales (EQ-VAS).

The exploratory objectives will include changes in tumor biomarkers such as CA-125 during treatment, exploring biomarkers related to efficacy and patient prognosis and changes in gene mutation before and after treatment from tumor tissue and blood.

Visiting Plan

HRD positive status will be screened by the next generation sequencing technology on peripheral blood and tumor tissue samples by using three classic indicators of genomic instability (LOH, loss of heterozygosity; TAI, telomeric allelic imbalance and LST, large scale state transitions). It takes 7 natural days from sampling to issuing the report, the same time as routine postoperative examination. Baseline data will be recorded at the screening visit, and it must be completed within 28 days before enrolment. Pre-assessment on the basis of parameters specified in Figure 2 will be performed within 3 days before tumor reduction surgery.

FIGURE 2

Figure 2 Follow-up plan. ¹In addition to the prescribed visit schedule, local researchers may conduct more frequent inspections as per patients’ requirements, which may include blood and urine routine examination, blood biochemistry, ECG, CT, and serum tumor biomarker (within one week); ²Refers to platinum-based chemotherapy post-surgery and included information collected from the patient’s medical record; ³It should not be completed >4 weeks before enrolment, excluding exceptional cases; ⁴Required to be completed within 72 hours of the start of the cycle 1 ( ± 1D); ⁵Required to be completed within 72 hours of the start of the cycle 2 ( ± 1D); ⁶Required to be completed within 72 hours from the beginning of cycle 2 treatment D28 (± 1D); ⁷Required to be completed within 3 days pre-operation; ⁸Once every 12 weeks after maintenance treatment and once every 24 weeks after two years; ⁹Includes name, age, gender, place of origin, contact details and date of admission; ¹⁰Time interval from last inspection should be >7 days, otherwise the inspection shall be canceled; ¹¹Includes heart rate, blood pressure, pulse and respiration; ¹²Records the tumor size at least; ¹³Recommended, non-mandatory; ¹⁴The United States Eastern Cooperative Oncology Group (ECOG) physical status scores; ¹⁵Blood or urine β-HCG test; ¹⁶Completed within two weeks before enrollment; ¹⁷Includes neutrophil/platelet count, and Hb level; ¹⁸Atleast 7 days before enrollment; ¹⁹Includes measurement of serum creatinine and electrolytes, total bilirubin, ALT/AST; ²⁰Time interval from the last inspection should not be <1 week, otherwise the inspection shall be canceled; ²¹Includes measurement of creatinine, urea nitrogen, and erythrocytes; ²²Includes testing of CA125, CA199, CEA, and HE4 related markers; ²³Biopsy done by laparoscopy, laparotomy, or coarse-needle aspiration; ²⁴Primary and metastatic tumor tissues obtained by laparotomy/laparoscopic tumor reduction surgery; ²⁵Samples in 2ml EDTA anticoagulant tube were used for HRD detection before enrollment and after two courses of treatment. Samples of 10ml Streck tube were collected before enrollment, D15 and D28 of the first course of chemotherapy, D15 of the second course of chemotherapy, and before tumor reduction surgery and subsequent therapy; ²⁶Abdominal CT or MRI is recommended for evaluation instead of ultrasound alone; ²⁷If blood routine tests are abnormal during maintenance treatment, then it should be carried out every 3 days and closely monitored until it becomes normal; ²⁸The operation record of the biopsy should be sent to the research center for record within 7 days; ²⁹Surgical records should be completed within 24 hours after the surgery and sent to the research center within 7 days for reference; ³⁰All adverse events to be documented from first day of receiving niraparib to post 30 days of treatment termination; ³¹All adverse events to be documented from first day of receiving niraparib to post 30 days of treatment termination; ³²Postoperative adverse events (D1 to D28); ³³Includes FACT-O, HADS, ISI, IPAQ, and EQ-VAS; ³⁴Recurrence and time of recurrence, death and time of death, whether to continue follow-up and last follow-up time are recorded; ³⁵The last follow-up before withdrawal; ³⁶After the completion of first-line chemotherapy, patients will receive maintenance treatment with niraparib within 12 weeks. ALT/AST, alanine aminotransferase/aspartate aminotransferase; CA, cancer antigen; CEA, carcinoembryonic antigen; CT, computed tomography; D, day; ECOG, Eastern Cooperative Oncology Group; ECG, electrocardiogram; EDTA, ethylenediaminetetraacetic acid; EQ-VAS, EuroQol-visual analog scales; FACT-O, Functional Assessment of Cancer Therapy-Ovarian; HADS, Hospital Anxiety and Depression Scale; Hb, hemoglobin; β-HCG, β-human chorionic gonadotropin; HE4, human epididymis protein 4; HRD, homologous recombination deficiency; IPAQ, International Physical Activity Questionnaire; ISI, Insomnia Severity Index; MRI, magnetic resonance imaging.

Patients will be followed up every three months during the first two years of the treatment, every six months for 2-5 years, and every year thereafter. Information on disease progression, safety and complications will be collected during follow-up and further recorded in the case report form (CRF). The treatment and follow-up plan has been presented in Figure 2. Survival follow-up will be conducted every 90 days (± 7 days) after drug withdrawal. Moreover, information of patients receiving new chemotherapy for the first time after the end of this study will be collected. Treatment can be terminated at any point during the study due to any of the following reasons: serious/life-threatening or intolerable treatment-related AEs, risk to patients, protocol violation, withdrawal of consent, pregnancy, and disease progression. The end of treatment (EOT) and follow-up visit should be completed if the study is discontinued or in case of patient’s withdrawal from the study. The following categories of concomitant medications are prohibited during the study period: granulocyte colony-stimulating factor (G-CSF), CYP1A2 sensitive substrates, anticoagulants and antiplatelet drugs, systemic glucocorticoids, other PARPis, radiation therapy, vaccines and hormonal contraceptives.

Effectiveness Evaluation

Computed tomography (CT) of the abdominal and pelvic cavity and other tumor areas with clinical indications will be performed at baseline and each follow-up (Figure 2). Tumor radiological imaging will use RECIST v1.1 criteria to classify objective remission status. Target lesions will be classified into CR, PR, SD, PD and non-evaluable (NE). Non-target lesions will be evaluated on the basis of CR, non-CR/non-disease progression (NN), PD, and NE.

Tumor response will be classified as PD for target lesions if there is ≥ 20% increase in the sum of the longest diameter of target lesions in comparison to the smallest sum longest diameter recorded in addition to an absolute increase of 5 mm whereas in case of non-target lesions, appearance of one or more new lesions or unequivocal progression of existing lesions will be considered as PD. New lesions refer to the appearance of new malignant lesions indicative of PD (18). In the case of PD, treatment should be terminated, and the follow-up should be continued. Target lesions of all patients will be measured by the same imaging technique and recorded in the CRF. Patients receiving at least two treatment cycles and one disease assessment or patients with early progression will be considered evaluable. Full analysis set (FAS) used for effectiveness evaluation will include all patients with primary gynecological malignancies (sub-grouped by tumor type), meeting the inclusion-exclusion criteria, with complete medical records.

Data and Sample Collection, Management, and Monitoring

Recurrent tumor tissue and blood samples collected will be sent to Tongji central laboratory. A detailed sample collection process is presented in Figure 3. During the treatment period, patients will receive relevant examinations and are expected to complete questionnaires related to the QOL as per schedule. Post-treatment, patients will be subjected to follow-up examination and telephone follow-up. The detailed data obtained from the patients will be recorded in the CRF and kept strictly confidential in the research center. All study records and original documents will be maintained and stored according to relevant regulations and guidelines, or by the research institution’s rules. The investigator will access the relevant raw data of the clinical study and will be responsible for reviewing CRF to determine completeness, accuracy, and consistency of the information with the source data. Moreover, CRF, raw laboratory data, and medical test results must be readily available for clinical inspectors, auditors, and health authorities.

FIGURE 3

Figure 3 Sample collection plan. ¹In addition to pathological sections, one copy of frozen, paraffin-embedded tissue for gene detection, and RNA preservation samples will be sent for sample retention. Also, samples in 2ml EDTA anticoagulant tube and in 10 ml streck tube should be sent to Tongji laboratory immediately for ctDNA sequencing; ²Tissue sample specimens should first meet the requirements of normal histopathological examination, and the remaining samples should be subjected to gene detection and tissue preservation according to the sample collection process; ³Tissue samples should be obtained at the time of biopsy. Sample in 2ml EDTA anticoagulant tube and in 10 ml streck tube should be sent to Tongji laboratory; ⁴Blood samples should be obtained within 72 hours after two weeks of the first cycle of treatment; ⁵Blood samples should be obtained within 72 hours on Day 1, 15 and the last day of the second course of treatment; ⁶Tissue samples should be obtained intraoperatively and blood samples within 72 hours after operation; ⁷Blood samples should be obtained once before adjuvant chemotherapy after tumor reduction surgery; ⁸The third and sixth cycles of chemotherapy were obtained on Day 1; ⁹During the maintenance treatment of niraparib, follow-up was conducted every 12 weeks to obtain blood samples; ¹⁰During the long-term follow-up after the withdrawal of maintenance treatment, follow-up was conducted every 12 weeks, and evaluation was conducted every 24 weeks up to two years to obtain blood samples; ¹¹Tissue samples should be obtained at the time of biopsy, and blood samples should be obtained within one week after confirming recurrence.

Safety Analysis

The most common adverse events observed in a previous study were Anemia, Nausea, Thrombocytopenia, etc. and the serious (grade ≥3) adverse events were anemia, thrombocytopenia and neutropenia (19). All AEs will be monitored 30 days after the last dose in this study. The research coordinator or data manager will summarize all serious AEs resulting in treatment withdrawal or deaths during or within 30 days of treatment termination on a per-patient basis. AEs will be coded in accordance with Medical Dictionary for Drug Regulatory Activities (MedDRA). Patient’s survival and myelodysplastic syndrome/acute myeloid leukemia (MDS/AML) information will be collected every 8 weeks from the beginning of treatment up to 90 days after the end of the study. The safety set (SS) used for safety evaluation will include patients using niraparib at least once and with relatively complete medical records.

Statistical Analysis

Hierarchical testing will be used to control the overall Type I error rate. First, ORR analysis will be conducted at the 1-sided alpha level of 0.05. If the result is positive, R0 resection rate analysis will be conducted with the 1-sided alpha level of 0.05. Descriptive measures will be used to summarize continuous variables (average value, standard deviation, median, maximum value, minimum value). Categorical variables will be expressed in frequency and percentage. The time to event analysis will be performed by the Kaplan Meier curve providing the median time to event. All data collected on CRF will be listed on a per-patient basis. Except for the date, the missing data will not be estimated. All statistical analysis will be calculated by SAS 9.4 statistical analysis software. Any deviations from the statistical methods given in the protocol will be reported in the final report as appropriate.

Sample Size

Sample size will be determined based on an intended statistical power of 90% (one-sided test, significance level of 5%). ORR will be the first primary endpoint as it is more objective and better reflects the effectiveness of niraparib neoadjuvant therapy. Based on the assumption that niraparib will be considered ineffective if the ORR is ≤ 20% (P0), and effective if the ORR is ≥ 40% (P1), this study can further proceed to large-scale clinical trials. The proposed study will utilize Simon’s two-stage design wherein in stage 1 a total of 24 patients will be enrolled. If the number of patients achieving objective response is >5, then the study will proceed to stage 2. In stage 2, a total of 21 patients were planned to be enrolled. A total of 53 patients will be included in the study, considering a possible 15% drop-out rate of patients. The intended ORR for achieving the primary endpoint in stage 2 will be >8 patients with objective response. Once the study achieves the first primary objective, the R0 resection rate of the second primary endpoint will be analyzed sequentially. Using 45 sample size, one-sided test, significance level of 5%, power was calculated to be 85.7%. Finally, the actual R0 resection rate and the confidence interval will be obtained according to statistical analysis of the data.

Discussion

To the best of our knowledge, this will be the first prospective multicenter study to evaluate the safety and effectiveness of niraparib alone as neoadjuvant treatment in advanced OC. The results from this study may propose a new treatment alternative for HRD positive patients with OC and extend the therapeutic applications of PARPi. Currently, not much is known about response of treatment-naïve patients to PARPi, and this long-lasting unsolved question has troubled many researchers.

So far, platinum-based chemotherapy is the only acceptable option for neoadjuvant treatment in patients with advanced OC (20). This study may extend the neoadjuvant treatment strategies in OC. Notably, the use of NACT for patients with OC increased from 17.6% in 2004 to 45.1% in 2016 (21). However, platinum- and paclitaxel-based NACT failed to grant any survival benefits in all existing randomized controlled trials (RCTs), leading to serious concerns on the effectiveness of NACT (10, 22). Oncogene targeted therapies have been proved to be more efficacious and safer than chemotherapy in serval other types of tumors, such as lung and breast cancer leading to a significantly improved prognosis and quality of life (23, 24). Similar therapies are rarely available for OC. Previously, ANTHALYA and GEICO 1205/NOVA clinical trials provided evidence on bevacizumab as a NACT in addition to chemotherapy in advanced OC, suggesting limited improvement in ORR (25). Most recently, the NUVOLA trial is recruiting patients to evaluate neoadjuvant olaparib and weekly TC (carboplatin plus paclitaxel) in unresectable OC (26). Therefore, it is imperative to explore more possibilities for neoadjuvant treatment in OC. Keeping in view the facts discussed above, our study was designed to find out whether niraparib neoadjuvant treatment could reduce surgical complexity and improve patients’ prognosis in advanced OC. Besides, this study could provide a foundation for future RCTs aiming to evaluate the potential PFS improvement with neoadjuvant niraparib therapy in patients with HRD positive OC.

The primary endpoint chosen for this study will ensure the maximum clinical translational potential since it represents the neoadjuvant treatment response as well as the complexity of the debulking surgery. Meanwhile, ORR, PFS, and OS could depict the anti-tumor potential of niraparib comprehensively in the short- and long-term respectively. Additionally, the sample size was calculated using Simon’s two-stage design. If niraparib was proven effective in a small population in the first stage, then only this study can proceed to the second stage and recruit more patients. More importantly, considering the safety concerns for the enrolled patients, serum CA125 levels will be measured biweekly. This will partially reflect the treatment responses and ensure patients with uncontrolled diseases withdrew from the experimental treatment on time. This design will not only secure the greatest clinical benefit to participants but also establish a scientifically reliable trial.

Several limitations of the study design can be acknowledged. Firstly, as of now, only Chinese patients will be included in the study. Secondly, no control group exists in this study, which should be notified during the result explanation and further appended in future studies.

Generally, this study may assess the potential of niraparib neoadjuvant treatment and IDS as a valid therapeutic strategy for patients with unresectable bulky tumors or poor general conditions. International investigators are welcome to contact and collaborate so that patients other than of Chinese origin can be enrolled in the study.

Data Availability Statement

The original contributions presented in the study are included in the article/supplementary material. Further inquiries can be directed to the corresponding authors.

Author Contributions

QG, DZ, and JL developed the study concept and protocol. HL and RL assisted in further development of the protocol. YH, LH, DM, and QG are responsible for the supervision of the clinical trial. QG has access to the final trial dataset. All authors contributed to the article and approved the submitted version.

Funding

This trial is funded by Pioneer Research Foundation of Tongji Hospital.

Conflict of Interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s Note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Acknowledgments

We thank Dr. Dharya Singh and Dr. Kaushik Subramanian of Indegene Pvt. Ltd, India for their help in language polishing. The abstract of this clinical trial was chosen as meeting posters in 2021 and 2022 (Oral Presentation) Society of Gynecologic Oncology (SGO) annual meetings.

Abbreviations

OC, Ovarian cancer; FIGO, The International Federation of Gynecology and Obstetrics; NACT, Neoadjuvant chemotherapy; IDS, Interval debulking surgery; Poly (ADP-ribose) polymerase (PARP) inhibitors; FDA, Food and Drug Administration; HRD, Homologous recombination deficiency; ORR, Objective response rate; PFS, Progression-free survival; CR, Complete response; PR, Partial response; SD; Stable disease; AEs, Adverse events; OS, Overall survival; GCP, Good Clinical Practices; CT, Computed tomography; RECIST, Response Evaluation Criteria in Solid Tumors; CTCAE, Common Terminology Criteria for Adverse Events; DCR, Disease control rate; CA125, Cancer antigen 125; GCIC, Gynecologic Cancer Intergroup Consensus; CFI, Chemotherapy-free interval; TFST, Time to first subsequent therapy; QOL, Quality of life; PRO, Patient report outcome; FACT-O, Functional Assessment of Cancer Therapy-Ovarian; HADS, Hospital Anxiety and Depression Scale; ISI, Insomnia Severity Index; IPAQ, International Physical Activity Questionnaire; EQ-VAS, EuroQol-visual analog scales; LOH, Loss of heterozygosity; TAI, Telomeric allelic imbalance; LST, Large scale state transitions; CRF, Case report form.

References

1. Cao W, Chen HD, Yu YW, Li N, Chen WQ. Changing Profiles of Cancer Burden Worldwide and in China: A Secondary Analysis of the Global Cancer Statistics 2020. Chin Med J (Engl) (2021) 134(7):783–91. doi: 10.1097/CM9.0000000000001474

PubMed Abstract | CrossRef Full Text | Google Scholar

2. Reid F. World Ovarian Cancer Coalition Atlas 2020. (2020). p. 42. Available at: https://worldovariancancercoalition.org/global-charter/road-to-the-charter/(2020) [Accessed January 4, 2022].

Google Scholar

3. Gadducci A, Guarneri V, Peccatori FA, Ronzino G, Scandurra G, Zamagni C, et al. Current Strategies for the Targeted Treatment of High-Grade Serous Epithelial Ovarian Cancer and Relevance of BRCA Mutational Status. J Ovarian Res (2019) 12(1):9. doi: 10.1186/s13048-019-0484-6

PubMed Abstract | CrossRef Full Text | Google Scholar

4. Takaya H, Nakai H, Takamatsu S, Mandai M, Matsumura N. Homologous Recombination Deficiency Status-Based Classification of High-Grade Serous Ovarian Carcinoma. Sci Rep (2020) 10(1):2757. doi: 10.1038/s41598-020-59671-3

PubMed Abstract | CrossRef Full Text | Google Scholar

5. Lheureux S, Gourley C, Vergote I, Oza AM. Epithelial Ovarian Cancer. Lancet (2019) 393(10177):1240–53. doi: 10.1016/S0140-6736(18)32552-2

PubMed Abstract | CrossRef Full Text | Google Scholar

6. Armstrong DK, Alvarez RD, Bakkum-Gamez JN, Barroilhet L, Behbakht K, Berchuck A, et al. NCCN Guidelines Insights: Ovarian Cancer, Version 1.2019. J Natl Compr Canc Netw (2019) 17(8):896–909. doi: 10.6004/jnccn.2019.0039

PubMed Abstract | CrossRef Full Text | Google Scholar

7. Armstrong DK, Alvarez RD, Bakkum-Gamez JN, Barroilhet L, Behbakht K, Berchuck A, et al. NCCN Clinical Practice Guidelines in Oncology: Ovarian Cancer (version 3.2021). (2021). Available at: https://www.nccn.org [Accessed January 4, 2022].

Google Scholar

8. Feng Z, Wen H, Li R, Liu S, Fu Y, Chen X, et al. Comparison of Survival Between Primary Debulking Surgery Versus Neoadjuvant Chemotherapy for Ovarian Cancers in a Personalized Treatment Cohort. Front Oncol (2020) 10:632195. doi: 10.3389/fonc.2020.632195

PubMed Abstract | CrossRef Full Text | Google Scholar

9. Al-Batran SE, Homann N, Pauligk C, Illerhaus G, Martens UM, Stoehlmacher J, et al. Effect of Neoadjuvant Chemotherapy Followed by Surgical Resection on Survival in Patients With Limited Metastatic Gastric or Gastroesophageal Junction Cancer: The AIO-FLOT3 Trial. JAMA Oncol (2017) 3(9):1237–44. doi: 10.1001/jamaoncol.2017.0515

PubMed Abstract | CrossRef Full Text | Google Scholar

10. Liu J, Jiao X, Gao Q. Neoadjuvant Chemotherapy-Related Platinum Resistance in Ovarian Cancer. Drug Discov Today (2020) 25(7):1232–8. doi: 10.1016/j.drudis.2020.04.015

PubMed Abstract | CrossRef Full Text | Google Scholar

11. Gee ME, Faraahi Z, McCormick A, Edmondson RJ. DNA Damage Repair in Ovarian Cancer: Unlocking the Heterogeneity. J Ovarian Res (2018) 11(1):50. doi: 10.1186/s13048-018-0424-x

PubMed Abstract | CrossRef Full Text | Google Scholar

12. Moore K, Colombo N, Scambia G, Kim BG, Oaknin A, Friedlander M, et al. Maintenance Olaparib in Patients With Newly Diagnosed Advanced Ovarian Cancer. N Engl J Med (2018) 379(26):2495–505. doi: 10.1056/NEJMoa1810858

PubMed Abstract | CrossRef Full Text | Google Scholar

13. Ray-Coquard I, Pautier P, Pignata S, Pérol D, González-Martín A, Berger R, et al. Olaparib Plus Bevacizumab as First-Line Maintenance in Ovarian Cancer. N Engl J Med (2019) 381(25):2416–28. doi: 10.1056/NEJMoa1911361

PubMed Abstract | CrossRef Full Text | Google Scholar

14. González-Martín A, Pothuri B, Vergote I, DePont Christensen R, Graybill W, Mirza MR, et al. Niraparib in Patients With Newly Diagnosed Advanced Ovarian Cancer. N Engl J Med (2019) 381(25):2391–402. doi: 10.1056/NEJMoa1910962

PubMed Abstract | CrossRef Full Text | Google Scholar

15. Coleman RL, Fleming GF, Brady MF, Swisher EM, Steffensen KD, Friedlander M, et al. Veliparib With First-Line Chemotherapy and as Maintenance Therapy in Ovarian Cancer. N Engl J Med (2019) 381(25):2403–15. doi: 10.1056/NEJMoa1909707

PubMed Abstract | CrossRef Full Text | Google Scholar

16. Mirza MR, Coleman RL, González-Martín A, Moore KN, Colombo N, Ray-Coquard I, et al. The Forefront of Ovarian Cancer Therapy: Update on PARP Inhibitors. Ann Oncol (2020) 31(9):1148–59. doi: 10.1016/j.annonc.2020.06.004

PubMed Abstract | CrossRef Full Text | Google Scholar

17. Moore KN, Secord AA, Geller MA, Miller DS, Cloven N, Fleming GF, et al. Niraparib Monotherapy for Late-Line Treatment of Ovarian Cancer (QUADRA): A Multicentre, Open-Label, Single-Arm, Phase 2 Trial. Lancet Oncol (2019) 20(5):636–48. doi: 10.1016/S1470-2045(19)30029-4

PubMed Abstract | CrossRef Full Text | Google Scholar

18. Nishino M, Jagannathan JP, Ramaiya NH, Van den Abbeele AD. Revised RECIST Guideline Version 1.1: What Oncologists Want to Know and What Radiologists Need to Know. AJR Am J roentgenol (2010) 195(2):281–9. doi: 10.2214/AJR.09.4110

PubMed Abstract | CrossRef Full Text | Google Scholar

19. Berek JS, Matulonis UA, Peen U, Ghatage P, Mahner S, Redondo A, et al. Safety and Dose Modification for Patients Receiving Niraparib. Ann Oncol (2018) 29(8):1784–92. doi: 10.1093/annonc/mdy181

PubMed Abstract | CrossRef Full Text | Google Scholar

20. Wright AA, Bohlke K, Armstrong DK, Bookman MA, Cliby WA, Coleman RL, et al. Neoadjuvant Chemotherapy for Newly Diagnosed, Advanced Ovarian Cancer: Society of Gynecologic Oncology and American Society of Clinical Oncology Clinical Practice Guideline. Gynecol Oncol (2016) 143(1):3–15. doi: 10.1016/j.ygyno.2016.05.022

PubMed Abstract | CrossRef Full Text | Google Scholar

21. Knisely AT, St Clair CM, Hou JY, Collado FK, Hershman DL, Wright JD, et al. Trends in Primary Treatment and Median Survival Among Women With Advanced-Stage Epithelial Ovarian Cancer in the US From 2004 to 2016. JAMA Netw Open (2020) 3(9):e2017517. doi: 10.1001/jamanetworkopen.2020.17517

PubMed Abstract | CrossRef Full Text | Google Scholar

22. Dabi Y, Huchon C, Ouldamer L, Bendifallah S, Collinet P, Bricou A, et al. Patients With Stage IV Epithelial Ovarian Cancer: Understanding the Determinants of Survival. J Transl Med (2020) 18(1):134. doi: 10.1186/s12967-020-02295-y

PubMed Abstract | CrossRef Full Text | Google Scholar

23. Wang J, Xu B. Targeted Therapeutic Options and Future Perspectives for HER2-Positive Breast Cancer. Signal Transduction Targeted Ther (2019) 4:34. doi: 10.1038/s41392-019-0069-2

CrossRef Full Text | Google Scholar

24. Falzone L, Salomone S, Libra M. Evolution of Cancer Pharmacological Treatments at the Turn of the Third Millennium. Front Pharmacol (2018) 9:1300. doi: 10.3389/fphar.2018.01300

PubMed Abstract | CrossRef Full Text | Google Scholar

25. Advani SH, Doval DC, Koppikar SB, Reddy PVA, Prasad S, Bapna A, et al. Use of Bevacizumab in Advanced Ovarian Cancer: Consensus From an Expert Panel Oncologists. Indian J Gynecol Oncol (2021) 19(1):8. doi: 10.1007/s40944-020-00485-6

CrossRef Full Text | Google Scholar

26. Marchetti C, Tudisco R, Salutari V, Pietragalla A, Scambia G, Fagotti A. Neoadjuvant Chemoteraphy in Unresectable Ovarian Cancer With Olaparib and Weekly Carboplatin Plus Paclitaxel: A Phase II, Open Label Multicenter Study (NUVOLA Trial). Int J gynecological Cancer Off J Int Gynecological Cancer Soc (2021) 31(8):1175–8. doi: 10.1136/ijgc-2021-002727

CrossRef Full Text | Google Scholar